

An update on the diagnosis and management of proteinuria in dogs and cats

Introduction

Proteinuria is a general term that describes any type of protein, including albumin, globulins, Bence Jones proteins, and others, in the urine. When proteinuria is detected, its potential clinical significance must be established. First it needs to be determined where the protein is coming from and whether it is prerenal, renal, or postrenal. If it is renal in origin, then the magnitude of proteinuria needs to be quantified and determined to be persistent or not.

With earlier recognition of chronic kidney disease (CKD) with the IDEXX SDMA® Test, veterinarians are encouraged to evaluate for proteinuria earlier. Evidence suggests an association between renal proteinuria and progression of CKD in dogs and cats; the greater the magnitude of proteinuria, the greater the risk for progression of renal disease and possible death.¹⁻⁴ It has been shown that treatments can decrease proteinuria, slow the progression of CKD, and improve survival.³⁻⁷

Screening tests for detecting protein on a urinalysis

There are several methods to measure protein on a routine urinalysis.

Colorimetric reagent strip (dipstick) method

The most common method for providing a semiquantitative measurement of protein on a urinalysis is by the colorimetric reagent strip (or dipstick) method. These dipsticks can either be read visually or by an automated urinalysis analyzer at a reference laboratory or in-house (IDEXX VetLab® UA™ Analyzer). Historically, the colorimetric reagent method included on a urine dipstick was considered to have both a high rate of false negatives and of false positives. However in recent years, the colorimetric reagent method has improved significantly, and because of this, IDEXX Reference Laboratories and other major university diagnostic laboratories have transitioned to this method.⁸

Sulfosalicylic acid (SSA) precipitation test

In the past, the sulfosalicylic acid (SSA) method was used for confirmation of protein detected on urinalysis due to high specificity. However, the very low sensitivity (prone to false negatives) makes SSA unsuitable for use as a screening test for proteinuria. As mentioned above, because of recent improvements in the colorimetric reagent method, SSA is no longer routinely performed at most veterinary diagnostic laboratories, including IDEXX Reference Laboratories.

Microalbuminuria test

The microalbuminuria test is a very sensitive test for determining if albumin is present in the urine. This test is limited to the detection of albumin only and does not detect other urine proteins that may contribute to renal proteinuria. The microalbuminuria test is prone to false positives, and determining the clinical significance of a positive result requires follow-up testing with a urine protein:creatinine (UPC) ratio.

Localizing origin of proteinuria

Localization of proteinuria as prerenal, renal, or postrenal is the first step in determining its clinical significance.

Prerenal proteinuria

Prerenal proteinuria can result from a number of processes that include systemic hypertension, overload of the glomeruli, and transient causes, such as shock, fever, and intense exercise. Hemoglobinuria (from hemolysis), myoglobinuria (from rhabdomyolysis) or immunoglobulins in the urine (from plasma cell cancers) may be seen with prerenal causes due to glomerular overload.

Postrenal proteinuria

Urinary tract inflammation, urinary tract infection (UTI), urinary neoplasia, or urolithiasis can cause postrenal proteinuria. If there is evidence of a UTI (white blood cells, red blood cells, and bacteriuria), a culture and minimum inhibitory concentration (MIC) susceptibility should be performed and the pet treated appropriately. After resolution of the UTI or other postrenal causes of proteinuria, a recheck urinalysis should be evaluated for proteinuria, and if still present, then a UPC should be performed.

The question often arises about if the amount of red blood cells in the urine can affect the UPC ratio. Studies in dogs have shown that unless urine is visibly red, red blood cells in the urine should not significantly increase the UPC ratio. A recent study in cats, however, reported that the UPC ratio could be increased in feline urine specimens that were not visibly hematuric, and sediment examination findings must be taken into account when interpreting UPC ratio results.⁹

Renal proteinuria

Proteinuria of renal origin results from two major mechanisms. Glomerular disease causes a loss of selective filtration that results in an increased amount of protein in the filtrate. Glomerular disease is present in about 50% of dogs with CKD, but it is rare in cats. Tubular dysfunction can result in low-level proteinuria leading to a failure to process and reabsorb the small amount of protein, mainly albumin, that traverses the glomerular barrier. Evidence supports an association between renal proteinuria and progression of CKD in dogs and cats; the greater the magnitude of proteinuria, the greater the risk for progression of renal disease and possible death.¹⁻⁴ Importantly, treatments that attenuated proteinuria in dogs and cats with CKD also have been associated with slowed progression of CKD, improved survival, or both.³⁻⁷

Quantifying renal proteinuria to guide management

Once prerenal and postrenal causes of proteinuria have been ruled out, a UPC ratio can be performed to quantify the degree of renal proteinuria to determine its clinical significance. The UPC ratio is a quantitative measure of all urine proteins. This test can be performed at a reference laboratory or in-house on the IDEXX Catalyst One® and Catalyst Dx® chemistry analyzers. By measuring both the urine creatinine along with the urine protein, the UPC ratio normalizes for variations in urine concentration. See figure 1 for guidance on when to perform a UPC ratio based on the colorimetric reagent strip method result.¹⁰




Figure 1. Guidelines for when to perform a UPC ratio in dogs and cats without prerenal or postrenal causes of proteinuria. Figure modified with permission from Elsevier.¹⁰

Investigating for cause of proteinuria

Investigating for and treating underlying systemic disease, such as infection, neoplasia, inflammatory disease, and immune-mediated disease, is recommended in both dogs and cats. If a UPC ratio of > 0.4 in a cat or > 0.5 in a dog is persistent, then a workup is warranted.^{10,11} This includes a minimum diagnostic database with complete blood count (CBC), chemistry panel that includes SDMA testing, urine culture, and blood pressure should be performed. Blood pressure should be evaluated and hypertension should be treated if present.

In dogs, vector-borne disease testing with the SNAP® 4Dx® Plus Test, thoracic radiographs, abdominal ultrasound, and testing for hyperadrenocorticism should be considered dependent on location, history, and physical examination. Evaluation for leptospirosis (antibody titers and PCR) should also be considered in dogs with acute proteinuria.

In cats, thyroxine measurement (if over age 4) and FeLV and FIV screening should be part of the initial testing. Imaging and additional testing, such as feline pancreatic lipase level (Spec fPL® Test or SNAP fPL® Test) should be considered depending on history and physical examination.¹²

If renal proteinuria is persistent and an underlying cause cannot be found, a renal biopsy may be considered.

International Renal Interest Society (IRIS) CKD guidelines

After diagnosis with CKD, the IRIS CKD staging guidelines should be applied to help guide therapy.¹³ Staging is based on a stable creatinine and SDMA. Substaging should be done for both blood pressure and proteinuria. Substaging for proteinuria is done based on the UPC ratio (see table 1).¹³ The magnitude of the UPC ratio, once determined to be persistently increased, can be used to guide treatment, monitor progression, and evaluate therapeutic response.

Substage	Urine protein: creatinine (UPC) ratio	
	Dogs	Cats
Nonproteinuric (NP)	< 0.2	< 0.2
Borderline proteinuric (BP)	0.2–0.5	0.2–0.4
Proteinuric (P)	> 0.5	> 0.4

Table 1. IRIS substaging by proteinuria in dogs and cats with CKD.¹³

Managing proteinuria

If treatment of concurrent disease does not result in reduction of proteinuria or if an underlying disease cannot be detected, then additional treatment is needed (for a UPC ratio of > 0.4 in cats and > 0.5 in dogs). The goal is to achieve a 90% reduction in proteinuria in cats and 50% reduction in dogs.¹¹

Diet

Diets moderately restricted in protein reduce the overall load of protein on the kidneys. By lowering circulating protein, there is less risk of protein overload across the filtration barrier and less tubular protein reabsorption. Commercial renal diets for dogs and cats are moderately restricted in protein content and are therefore recommended in pets with protein-losing nephropathy (PLN).¹¹

Angiotensin converting enzyme (ACE) inhibitors

ACE inhibitors reduce proteinuria by reducing glomerular capillary pressure by dilating the efferent renal arteriole. Studies in dogs have shown a decreased risk in progressive azotemia and increased survival.^{5,6} There is no benefit of using benazepril over enalapril in either dogs or cats other than that benazepril can often be dosed once daily.⁹

Angiotensin receptor blocker (ARB)

Telmisartan is an angiotensin I receptor blocker that spares the beneficial effects of the angiotensin II receptor. It has been shown to be as effective as benazepril in controlling proteinuria in cats with CKD.¹⁴

Omega-3 (eicosapentaenoic acid) supplementation

Dogs consuming omega-3 polyunsaturated fatty acids (n-3 PUFAs) have lower mortality, increased renal function, and reduced proteinuria and cholesterol. Prescription renal diets are often supplemented with n-3 PUFAs.¹¹

Immunosuppressant therapy

Immunosuppressants should be reserved for use when a diagnosis of immune-mediated glomerulonephritis has been made via a renal biopsy. They should be considered only when proteinuria in a dog is severe, persistent, and/or progressive and there is no identified contraindication to immunosuppressive therapy. Mycophenolate alone or in combination with prednisolone should be considered when there is profound proteinuria, hypoalbuminemia, nephrotic syndrome, or rapidly progressive azotemia. For stable or slowly progressive glomerular diseases, mycophenolate or chlorambucil alone or in combination with azathioprine on alternating days should be considered.¹⁵

Anticoagulants

Low-dose acetylsalicylic acid (aspirin) should be considered as an adjunct therapy for protein-losing nephropathies, given that antithrombin III (ATIII) is often lost into the urine, making animals hypercoagulable. It is recommended to consider treatment in all cases with hypoalbuminemia. The dose of aspirin recommended is 0.5–1.0 mg per kg of body weight daily in dogs and 5 mg every 72 hours in cats.¹⁶

Monitoring proteinuria

After initial treatment for proteinuria and after changes are made to therapy, follow-up should be in 1–4 weeks for physical examination, chemistry panel (including serum albumin, SDMA, and creatinine), UPC ratio, and blood pressure. Rechecks should be performed every 3–6 months in stable patients.

Ordering information

Test code	Test name and contents
910	Urinalysis
9101	Add-on Physical, chemical, and microscopic analyses
994	Urine Protein:Creatinine Ratio
997	Add-on
92	Urinalysis with UPC
2326	Urinalysis with Reflex UPC (if Indicated) If the urinalysis is positive for protein and the sediment is not active, a urine protein:creatinine (UPC) ratio is automatically performed. If the urinalysis is negative for protein, or if there is an active sediment (white blood cells \geq 6/hpf, red blood cells \geq 100/hpf, color is red or pink, and/or bacteria are seen), the UPC ratio will not be performed. The test price is the same whether or not a UPC ratio is performed
3744	Renal Profile, Complete with Reflex UPC (if Indicated)
37449999	IDEXX CBC™ Albumin, albumin:globulin ratio, BUN, BUN: creatinine ratio, calcium, chloride, cholesterol, creatinine, globulin, phosphorus, potassium, total protein, IDEXX SDMA® Test, sodium, sodium:potassium ratio, anion gap, TCO ₂ (bicarbonate), IDEXX CBC-Select™, urinalysis with reflex urine protein:creatinine (UPC) ratio if indicated Note: If the urinalysis is positive for protein and the sediment is not active, a UPC ratio is automatically performed. If the urinalysis is negative for protein, or if there is an active sediment (white blood cells \geq 6/hpf, red blood cells \geq 100/hpf, color is red or pink, and/or bacteria are seen), the UPC ratio will not be performed. The test price is the same whether or not a UPC ratio is performed.

Specimen requirements

5 mL urine in a sterile container. For the Renal Profile, also include 2 mL serum and 1 mL LTT for the chemistry and CBC.

Customer support services

IDEXX supports your practice with our customer support, technical support, and medical consulting services teams, including our diagnostic support veterinarians and board-certified veterinary specialists.

References

1. Jacob F, Polzin DJ, Osborne CA, et al. Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. *JAVMA*. 2005;226(3):393-400.
2. Syme HM, Markwell PJ, Pfeiffer D, Elliott J. Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria. *J Vet Intern Med*. 2006;20(3):528-535.
3. Jepson RE, Elliott J, Brodbelt D, Syme HM. Effect of control of systolic blood pressure on survival in cats with systemic hypertension. *J Vet Intern Med*. 2007;21(3):402-409.
4. King JN, Tasker S, Gunn-Moore DA, Strehlau G, BENRIC Study Group. Prognostic factors in cats with chronic kidney disease. *J Vet Intern Med*. 2007;21(5):906-916.
5. Grodecki KM, Gains MJ, Bauman R, et al. Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. *J Comp Pathol*. 1997;117(3):209-225.
6. Grauer GF, Greco DS, Getzy DM, et al. Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis. *J Vet Intern Med*. 2000;14(5):526-533.
7. Mizutani H, Koyama H, Watanabe T, et al. Evaluation of the clinical efficacy of benazepril in the treatment of chronic renal insufficiency in cats. *J Vet Intern Med*. 2006;20(5):1074-1079.
8. Comparison of automated colorimetric reagent strip method and sulfosalicylic acid (SSA) precipitation method for detection of urine protein. IDEXX internal study available at www.idexx.com/SSAstudy.
9. Vientós-Plotts AI, Behrend EN, Chew D, Welles EG, Lee HP. Effect of hematuria on urine protein:creatinine ratio in cats [ACVIM Abstract NU14]. *J Vet Intern Med*. 2015;29(4):1214.
10. Naby MB. Re-evaluating urine dipstick protein in dogs: when should you be concerned? *Adv Small Anim Med Surg*. 2011;24(11):1-3.
11. Harley L, Langston C. Proteinuria in dogs and cats. *Can Vet J*. 2012;53(6):631-638.
12. RIS Canine GN Study Group Diagnosis Subgroup, Littman MP, Daminet S, Grauer GF, Lees GE, vanDongen AM. Consensus recommendations for the diagnostic investigation of dogs with suspected glomerular disease. *J Vet Intern Med*. 2013;27(Suppl 1):S19-26.
13. International Renal Interest Society. 2015 IRIS CKD Staging Guidelines. www.iris-kidney.com. Accessed June 22, 2018.
14. Sent U, Gossli R, Elliott J, Syme HM, Zimmering T. Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kidney disease. *J Vet Intern Med*. 2015;29(6):1479-87.
15. IRIS Canine GN Study Group Established Pathology Subgroup, Segev G, Cowgill LD, Heiene R, Labato MA, Polzin DJ. Consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology. *J Vet Intern Med*. 2013;27(Suppl 1):S44-54.
16. Littman MP. Protein-losing nephropathy in small animals. *Vet Clin Small Anim*. 2011;41(1):31-62.

Published October 2018

The information contained herein is intended to provide general guidance only. As with any diagnosis or treatment, you should use clinical discretion with each patient based on a complete evaluation of the patient, including history, physical presentation and complete laboratory data. With respect to any drug therapy or monitoring program, you should refer to product inserts for a complete description of dosages, indications, interactions and cautions.

© 2018 IDEXX Laboratories, Inc. All rights reserved. • 09-2099475-01
All ®/TM marks are owned by IDEXX Laboratories, Inc. or its affiliates in the United States and/or other countries.
The IDEXX Privacy Policy is available at idexx.com.

